156 related articles for article (PubMed ID: 30850839)
21. IL-2 receptor γ-chain molecule is critical for intestinal T-cell reconstitution in humanized mice.
Denton PW; Nochi T; Lim A; Krisko JF; Martinez-Torres F; Choudhary SK; Wahl A; Olesen R; Zou W; Di Santo JP; Margolis DM; Garcia JV
Mucosal Immunol; 2012 Sep; 5(5):555-66. PubMed ID: 22569301
[TBL] [Abstract][Full Text] [Related]
22. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
[TBL] [Abstract][Full Text] [Related]
24. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
25. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
26. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
27. Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection.
Lee BT; Horwich BH; Chopra S; Ahearn A; Han HH
Liver Transpl; 2019 Dec; 25(12):1845-1848. PubMed ID: 31408574
[No Abstract] [Full Text] [Related]
28. Expression of glucocorticoid receptor shows negative correlation with human B-cell engraftment in PBMC-transplanted NOGhIL-4-Tg mice.
Seki T; Miyamoto A; Ohshima S; Ohno Y; Yasuda A; Tokuda Y; Ando K; Kametani Y
Biosci Trends; 2018 Jul; 12(3):247-256. PubMed ID: 29806632
[TBL] [Abstract][Full Text] [Related]
29. Hypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency.
Martinez-Torres F; Nochi T; Wahl A; Garcia JV; Denton PW
PLoS One; 2014; 9(10):e108663. PubMed ID: 25271886
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.
McMillan JM; Cobb DA; Lin Z; Banoub MG; Dagur RS; Branch Woods AA; Wang W; Makarov E; Kocher T; Joshi PS; Quadros RM; Harms DW; Cohen SM; Gendelman HE; Gurumurthy CB; Gorantla S; Poluektova LY
J Pharmacol Exp Ther; 2018 May; 365(2):272-280. PubMed ID: 29476044
[TBL] [Abstract][Full Text] [Related]
31. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
32. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
33. HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice.
Ohno Y; Ohshima S; Miyamoto A; Kametani F; Ito R; Tsuda B; Kasama Y; Nakada S; Kashiwagi H; Seki T; Yasuda A; Ando K; Ito M; Tokuda Y; Kametani Y
Sci Rep; 2021 Jun; 11(1):12798. PubMed ID: 34140620
[TBL] [Abstract][Full Text] [Related]
34. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
35. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
36. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
Nguyen V; Huq M
J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
[TBL] [Abstract][Full Text] [Related]
37. Improved B cell development in humanized NOD
Jangalwe S; Shultz LD; Mathew A; Brehm MA
Immun Inflamm Dis; 2016 Dec; 4(4):427-440. PubMed ID: 27980777
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
[TBL] [Abstract][Full Text] [Related]
39. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
40. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
Choi B; McBride A; Scott AJ
Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
